Skip to main content

Peer Review reports

From: Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial

Original Submission
8 Dec 2022 Submitted Original manuscript
20 Jan 2023 Reviewed Reviewer Report
4 Feb 2023 Reviewed Reviewer Report
6 Mar 2023 Author responded Author comments - Zhe-Yu Hu
Resubmission - Version 2
6 Mar 2023 Submitted Manuscript version 2
27 Mar 2023 Reviewed Reviewer Report
13 Jun 2023 Author responded Author comments - Zheyu Hu
Resubmission - Version 3
13 Jun 2023 Submitted Manuscript version 3
Publishing
14 Jun 2023 Editorially accepted
26 Jun 2023 Article published 10.1186/s12916-023-02943-2

You can find further information about peer review here.

Back to article page